	Application No.	Applicant(s)
Notice of Allowability	09/493,795	WATKINS ET AL.
	Examiner	Art Unit
	Gabriele E. BUGAISKY	1653
The MAILING DATE of this communication appear All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI	(OR REMAINS) CLOSED in this or other appropriate communical GHTS. This application is subje	application. If not included ition will be mailed in due course. THIS
 This communication is responsive to the amendment of 1/2 The allowed claim(s) is/are 1,2,8,9 and 39. The drawings filed on are accepted by the Examine Acknowledgment is made of a claim for foreign priority una) All b) Some* _ c) None of the: Certified copies of the priority documents have 	r. nder 35 U.S.C. § 119(a)-(d) or (f)	
2. Certified copies of the priority documents have been received in Application No		
 Copies of the certified copies of the priority doc International Bureau (PCT Rule 17.2(a)). * Certified copies not received: 	cuments have been received in t	his national stage application from the
 5. Acknowledgment is made of a claim for domestic priority un reference was included in the first sentence of the specification. (a) The translation of the foreign language provisional at the first sentence of the specification or in an Application. 6. Acknowledgment is made of a claim for domestic priority un in the first sentence of the specification or in an Application. Applicant has THREE MONTHS FROM THE "MAILING DATE" of below. Failure to timely comply will result in ABANDONMENT of the first sentence of the specification. 7. A SUBSTITUTE OATH OR DECLARATION must be submin INFORMAL PATENT APPLICATION (PTO-152) which give the first sentence of the specification or in an Application. 8. CORRECTED DRAWINGS (as "replacement sheets") must be submin to the first sentence of the specification or in an Application. 	ation or in an Application Data Shapplication has been received. Inder 35 U.S.C. §§ 120 and/or 12 I Data Sheet. 37 CFR 1.78. I this communication to file a replication. THIS THREE-I Itted. Note the attached EXAMINGS reason(s) why the oath or dece	neet. 37 CFR 1.78. 1 since a specific reference was included y complying with the requirements noted MONTH PERIOD IS NOT EXTENDABLE IER'S AMENDMENT or NOTICE OF
 (a) ☐ including changes required by the Notice of Draftspers 1) ☐ hereto or 2) ☐ to Paper No (b) ☐ including changes required by the proposed drawing c (c) ☐ including changes required by the attached Examiner's Identifying indicia such as the application number (see 37 CFR 1 each sheet. Replacement sheet(s) should be labeled as such in the 	on's Patent Drawing Review (Ponts or Patent Drawing Review (Ponts or Patent Drawing Review (Ponts on the Drawing Review (Ponts on th	s been approved by the Examiner. ne Office action of Paper No awings in the front (not the back) of
9. DEPOSIT OF and/or INFORMATION about the depo- attached Examiner's comment regarding REQUIREMENT FOR T	sit of BIOLOGICAL MATERIA	AL must be submitted. Note the
Attachment(s)		
1 Notice of References Cited (PTO-892) 2 Notice of Draftperson's Patent Drawing Review (PTO-948) 3 Information Disclosure Statements (PTO-1449 or PTO/SB/08 Paper No. 0503	6 Interview Summa	ry (PTO-413), Paper No
	77 7⊠ Examiner's Amen	
4☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material	8∏ Examiner's Stater 9∏ Other .	Gabriele E. BUGAISKY Primary Examiner Art Unit: 1653

Application/Control Number: 09/493,795

Art Unit: 1653

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mr. Jeffrey Ihnen on 12 March 2004.

The application has been amended as follows:

Claim 1, line 1, add "and purified" after "isolated",

line 27, delete "such as".

Claim 2, line 1, add "and purified" after "isolated",

line 4, delete "(Dor" and replace with "(D or",

line 9, delete "homoargine", and replace with "homoarginine",

line 16, change "homosysteine" to "homocysteine"

Claim 39, line 1, add "and purified" after "isolated"

The term "and purified" ensures that the claimed peptide is distinguished from its mere presence in venom isolated from a snail.

The information disclosure statement of 5/2003 was matched with the application subsequent to the last Action. All references have been considered.

Art Unit: 1653

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gabriele E. BUGAISKY whose telephone number is (571) 272-0945. The examiner can normally be reached on Tues.- Fri 8:15 AM-1:45 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher SF Low can be reached on (571) 272-0951. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (571) 272-0700.

Gabriele E. BUGAISKY
Primary Examiner

Art Unit 1653